For its third fiscal quarter (ending September 30), Bristol-Myers Squibb Co (NYSE: BMY) has reported a -36% decline in E.P.S. from $0.94 a year ago to $0.60 in the current quarter. E.P.S. were $-3.58 for the latest four quarters through September 30 versus $3.97 for the same period a year ago — a decline of -190%.
Recent Price Action
On 10/31/24, Bristol-Myers Squibb Co (NYSE: BMY) stock enjoyed a very large increase of 5.9%, closing at $55.77. Moreover, this advance was accompanied by unusually high trading volume at 181% of normal. The stock has risen 5.1% during the last week and has performed in line with the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, BMY is expected to continue to be a major Value Builder.
Bristol-Myers Squibb has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing highly consistent signals. Bristol-Myers Squibb has a neutral Power Rating of 54 and a neutral Appreciation Score of 54, leading to the Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment